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Highlights 
 State of renal impairment is important for forensic toxicology 
interpretation 
 Creatinine is commonly analysed clinically but eGFR is better 
 eGRF has better sensitivity and specificity for scored renal function  
 interpretation of renal function from post mortem samples is 
difficult 
 
Abstract 
The determination of the role that drugs may have played in a death is 
an important part of the investigation into unexplained deaths.  Renal 
impairment may lead to a reduction in drug excretion rate and therefore 
an accumulation of drugs or metabolites, leading to possible toxic or 
lethal effects. Creatinine levels are known to be stable in the post 
mortem period and in life can give an indication of kidney function. There 
are however widely reported limitations when using creatinine in 
isolation and so we investigated the usefulness of using estimated 
glomerular filtration rate (eGFR) for scoring an individual as having renal 
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impairment using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula. We analysed unpreserved vitreous for 
creatinine in 812 individuals using an isotope dilution mass spectrometry 
(ID-MS) traceable enzymatic. We found that the biochemical analysis of 
post mortem vitreous creatinine and subsequent calculation of eGFR is 
a useful adjunct to the standard testing that takes place during a post-
mortem examination and can assist in death investigation. Using an 
eGFR of <60 mL/min/1.73 m2 gave a sensitivity of 94.3% and specificity 
of 97.3% when scoring an individual as having renal impairment. We 
therefore recommend the calculation of eGFR for the determination of 
possible renal impairment in post mortem investigations. It is, of course, 
always pertinent to interpret any results using a wealth of case 
information. Extreme caution should be exercised in cases where 
insufficient clinical information/history is available, particularly in cases in 
which there is suspected diabetic ketoacidosis, dehydration or 
hospitalisation prior to death.  
 
1. Introduction 
The determination of the role that drugs may have played in a death is 
an important part of the investigation into unexplained deaths.  Renal 
impairment may lead to a reduction in drug excretion rate and therefore 
an accumulation of drugs or metabolites, leading to possible toxic or 
lethal effects.  This accumulation is more likely if the usual excretion of 
drugs or their metabolites is through a urinary route (see table 1).  Any 
renal impairment may or may not have been diagnosed before death, 
and medical records may or may not be available, therefore a suitable 
method for post mortem investigation is required in order to identify the 
presence of renal impairment.   
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In living patients there are two recognised clinical classifications with 
diminished kidney function, 1) chronic kidney disease (CKD) and 2) 
acute kidney injury (AKI) both of which would be expected to reduce 
renal excretion of some drugs [1]. CKD is a condition characterised by a 
gradual loss of kidney function over time (months, years, decades) [1]. 
AKI is a disorder that is characterised by a rapid loss (hours to days) of 
the kidney’s excretory function [2]. Although there are clear 
guidelines/algorithms for the determination of AKI and CKD in the living, 
the status of kidney function close to the time of death, without previous 
medical history is difficult to determine using biochemical analysis of 
post mortem samples alone. This is because definitive confirmation of 
both CKD and AKI requires analysis of serum at multiple time points [3].  
The clinically acceptable measure of kidney function is the determination 
of glomerular filtration rate (GFR), this measure is directly related to the 
number of functioning nephrons in the kidney. Clinically it is common to 
determine GFR using endogenous biochemical markers such as 
creatinine [4,5] and urea [6]. In the post mortem environment both 
creatinine and urea have been shown to be stable in vitreous humour so 
can potentially be used to determine kidney function close to the time of 
death [7–11].  
Although creatinine was the preferred measure of GFR, creatinine 
concentration is affected by various factors (such as age, gender, 
ethnicity, muscle wasting disorders, recent intake of cooked meat and 
drugs that can block tubular secretion of creatinine [12]). In order to 
overcome some of these limitations of creatinine measurements alone, 
equations that estimate GFR (eGFR) from creatinine concentration have 
been developed (such as the Cockcroft and Gault [13], MDRD [14] and 
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CKD-EPI [15]). In the UK, the CKD-EPI equation (given below) is the 
recommended equation for determination of eGFR [16]. 
 
𝑒𝐺𝐹𝑅 = 141 × min (
𝑆𝐶𝑟 × 0.011312
𝑘
, 1)
𝛼
× max (
𝑆𝐶𝑟 × 0.011312
𝑘
, 1)
−1.209 
× 0.993𝑎𝑔𝑒 × 1.018[𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒]
× 1.159 [𝑖𝑓 𝑏𝑙𝑎𝑐𝑘] 
 
eGFR (estimated glomerular filtration rate) = mL/min/1.73 m2, SCr 
(standardized serum creatinine) = mg/dL, age = years,  is 0.7 for 
females and 0.9 for males, α is        -0.329 for females and -0.411 for 
males, min indicates the minimum of serum creatinine/ or 1 and max 
indicates the maximum of serum creatinine/ or 1. 
Although eGFR is the preferred method to assess kidney function, to 
date the only study to investigate eGFR in the post mortem environment 
[17] was limited by sample size and used the MDRD equation, rather 
than the recommend CKD-EPI equation. 
The aim of this study is to determine if eGFR is a suitable method to 
determine the presence of previously undiagnosed renal impairment for 
post mortem investigations.  
 
2. Materials and Methods 
2.1 Sample Collection 
Where available, vitreous humour samples were collected and analysed 
as part of routine Coronial procedure between January 2014 and 
AC
CE
PT
D M
AN
US
CR
IPT
Page 5 of 24 
 
December 2016 at the Forensic Toxicology laboratory, University 
Hospitals of Leicester (UHL) NHS Trust. Vitreous humour was sampled 
from both eyes by aspiration using a sterile needle and syringe as part of 
the autopsy. The sampled vitreous was immediately mixed in a 
preservative free tube. The vitreous samples were then transported to 
the analytical laboratory and stored at 4°C for up to 1 week before 
analysis.  
 
2.2 Sample Population  
The case inclusion criteria for the study included a post mortem interval 
not exceeding 72 hours and the availability of vitreous humour.  812 
cases were included in the study (216 females and 596 males; age 18 – 
95 years of age). The certified causes of death included: Acute traumatic 
deaths (6); aircraft accident (6); hit by a train (12); fall from height (49); 
drowning (14); drug toxicity (172); ethanol toxicity (30); hanging (157); 
head injury (23); alcoholic ketoacidosis (30); diabetic ketoacidosis (40); 
road traffic collision (210) and stab wound(s) (32). 37 individuals in the 
study had known renal impairment (KRI) (as stated in the provided 
clinical history or medical records) and were not included in any of the 
other groups.    
 
2.3 Sample Analysis 
Immediately before analysis for creatinine the undiluted vitreous 
samples were centrifuged at 11,000 rpm for 10 minutes.  The 
centrifuged samples then were measured for creatinine using the 
Siemens standard methodology (Siemens Advia® 2400, Siemens 
Healthcare, Surrey, UK) based on the method of Tanganelli and 
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colleagues [18]. This assay is traceable to National Institute for 
Standards and Technology (NIST) SRM967. The clinical reference 
ranges for creatinine at University Hospitals of Leicester are 60–
120 μmol/L. The eGFR reference ranges are eGFR 90 mL/min/1.73 m2 
(normal), 60-89 (mild reduction), 45-59 (mild to moderate reduction) 
(from reference [19]).  
2.5 Determination of “kidney impairment” in post mortem cases. 
Without antemortem diagnosis of kidney impairment it is not possible to 
definitively determine renal impairment from a post mortem analysis. We 
therefore “scored” individuals as having “kidney impairment” based on 
either a creatinine concentration of >120 μmol/L or an eGFR of either 
<60 mL/min/1.73 m2 or <90 mL/min/1.73 m2. This allowed the 
comparison of the prevalence of “kidney impairment” in the living (based 
on population data [20]) and the deceased (based on samples collected 
at autopsy).      
 
2.5 Data Analysis 
From the analytical results of creatinine eGFR was calculated with the 
CKD-EPI equation using Microsoft Excel 2013 (Microsoft. Redmond, 
WA. USA). Data were analysed with GraphPad Prism 6.01 (GraphPad 
Software, Inc. CA 92037 USA).  Before any further analysis, outliers 
were removed using the GraphPad ROUT method (Q = 1%). Normality 
of distribution was tested using the D’Agostino-Pearson omnibus 
normality test. Possible differences between the parameters investigated 
were tested using nonparametric testing (Kruskal-Wallis test (one-way 
ANOVA)). Sensitivity and specificity of creatinine and eGFR for the 
determination of scored renal impairment used KRI (control) and 
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hanging (patient) data with ROC analysis in GraphPad Prism (95% 
confidence limits). Statistical significance (α) was set at p<0.05 for all 
tests. As most of the groups in this study were not normally distributed 
data are given as median with ranges. 
 
3. Results  
 
3.1 Comparison of creatinine concentrations and eGFR compared to 
cause of death 
The ranges of creatinine and eGFR for the KRI group (based on medical 
history) and the cause of death groups are shown in Fig 1 (creatinine) 
and Fig 2 (eGFR). There were statistically significant higher creatinine 
concentrations in the KRI group compared to all other causes of death 
groups (apart from death from diabetic ketoacidosis) (Table 2). When 
investigating eGFR the KRI group showed statistically significantly lower 
eGFR than of all of the other causes of death (apart from diabetic 
ketoacidosis) similar to creatinine results (Table 2).  
 
3.2 Accuracy of creatinine and eGFR ranges determining renal 
impairment in known cases 
In 37 patients there was documented kidney impairment, this allowed a 
comparison of vitreous creatinine and calculated eGFR to the clinical 
reference ranges in serum. The median concentration of creatinine in all 
cases (n = 812) was 66 mol/L with a range of 3 – 1155 mol/L; this 
compared to a median creatinine concentration of 220 mol/L with a 
range of 86 – 1155 for KRI cases (n =37). The median eGFR in all cases 
(n = 812) was 112 mL/min/1.73 m2 with a range of 2 – 3765 mL/min/1.73 
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m2; this compared to a median concentration of 23 mol/L with a range 
of 2 – 62 for KRI cases (n = 37).  
We determined the accuracy of the creatinine and eGFR reference 
ranges to score individuals as having “kidney impairment” with 
individuals with known to have kidney impairment. The creatinine 
reference range (>120 µmol/L) scored 89% (33/37) of individuals as 
having kidney impairment with the eGFR of <60 mL/min/1.73 m2 scoring 
(97% of cases (36/37) and an eGFR <90 mL/min/1.73 m2 scoring 100% 
of cases (37/37). 
 
3.3 Sensitivity and specificity of creatinine and eGFR for determination 
of scored renal failure  
The group of individuals who had died due to hanging were determined 
to be the group that would be least likely to exhibit altered renal function 
due to the death process. The individuals in this group were all declared 
deceased at the scene. This allowed the determination of the sensitivity 
and specificity of the various reference ranges for renal impairment. The 
analysis showed that based on an eGFR of <60 mL/min/1.73 m2 to score 
renal impairment sensitivity was 94.3 %, specificity 97.3 %. With an 
eGFR of <90 mL/min/1.73 m2, sensitivity 86.0 %, specificity 100.0 %. 
Creatinine >120mol/L gave a sensitivity 98.6 %, specificity 87.5 %.  
 
3.4 Prevalence of KRI in the general UK population compared to 
individuals scored as having “kidney impairment” based on post mortem 
analysis 
The prevalence of individuals who were scored as having kidney 
impairment based on creatinine levels of >120 mol/L or an eGFR <60 
mL/min/1.73 m2 in post mortem vitreous analysis were compared to the 
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prevalence in the general population based on age (Fig 3). As expected, 
there was an increase in the number of individuals who were scored as 
having renal impairment as age increased. On average 7% more males 
and 6% more females were scored as being renally impaired compared 
to the population average when using creatinine as a measure to score 
renal impairment. This increased to 13% (male) and 18% (female) when 
eGFR (<60 mL/min/1.73 m2) was used to score renal impairment and 
was 32.3% (male) and 30% (female) greater than in the general 
population when eGFR (<90) mL/min/1.73 m2 was used. 
 
4. Discussion 
In forensic toxicology it is important to ascertain, where possible, the 
presence of kidney impairment in an individual as this diagnosis may go 
some way to explain the presence of raised drug concentrations in 
deceased individuals. Creatinine has previously been demonstrated to 
be stable in the post mortem period in post humour after death [7–11]. 
Creatinine has also been shown to be useful for the diagnosis of renal 
impairment in cases where a medical history is unavailable [7,8,21]. 
However, the use of creatinine concentration suffers from limitations that 
in clinical practice have been partially overcome by determining the 
eGFR of an individual. In this study we looked at a series of 812 deaths 
in which clinical information and post mortem vitreous humour samples 
were available. We aimed to determine if eGFR calculated from vitreous 
creatinine was a better measure than post mortem vitreous creatinine 
concentrations alone for the determination of possible renal impairment 
(scoring as renal impairment). We also used these data to compare the 
prevalence of “kidney impairment” in the normal population and our 
sample population.  
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In 37 patients there was documented kidney impairment, which allowed 
a comparison of vitreous creatinine and calculated eGFR levels in a 
“control” group. When using the reference ranges and eGFR levels the 
vitreous creatinine scored 89% of individuals correctly (as having renal 
impairment) with eGFR scoring between 97-100% of individuals as 
being renally impaired (depending on the eGFR used). The vitreous 
humour results for this sample group (KRI) demonstrate that 
determination of kidney function from post mortem vitreous correlates 
well with known clinical information. Based on the calculated sensitivity 
(probability that a test result will be positive when the renal impairment is 
actually present) eGFR (97-100%) performed better than creatinine 
(89%). In order to determine the sensitivity and specificity of the eGFR 
and creatinine reference ranges in scoring renal impairment we used the 
KRI group and the “hanging” group. The “hanging” cause of death group 
were determined to be the group that would be least likely to have 
altered renal function (due to the manner of death). eGFR showed larger 
sensitivities and specificities than creatinine in the determination of 
kidney impairment. These data suggest that eGFR is a better method to 
score kidney impairment from post mortem vitreous samples than 
creatinine alone. It is important to note that the “hanging” group may not 
be truly representative of a “negative” group for kidney impairment and 
ideally group(s) of individuals with a with both positive and negative 
medical histories for kidney impairment would be used to determine 
more accurate sensitivities and specificities for the tests.  
As mentioned above the interpretation of renal impairment can be 
complicated by the manner of death and also any co-morbidities 
present. AKI could manifest as part of the death process, especially if 
death was not instantaneous and the individual was hospitalised before 
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death. It has been suggested that deaths that involve burns, fires, 
hyperthermia and dehydration may result in increased creatinine in the 
blood due to muscle catabolism or from thermal muscle damage, cases 
in which increased creatinine could be misinterpreted as renal 
impairment [7,8].  
Clinical guidelines also suggest that AKI, and thus renal impairment, 
may be present in individuals with heart failure, liver disease, 
dehydration, hypovolemia (i.e. blood loss, fluid loss), drugs with 
nephrotoxic potential, hypotension, diabetes, chronic kidney disease, 
blockage of urinary tract and major surgery [22].  For example, in a study 
of 1,743 patients treated for renal failure the most commonly associated 
conditions were sepsis (43.8%), major surgery (39.1%), low cardiac 
output (29.7%) and hypovolemia (28.2%) [22]. These studies show that 
the determination of renal impairment from post mortem sample analysis 
may be problematic. A further indication of the scale of prevalence of 
AKI can be seen in a study from the UK in which 8 - 16% of people 
admitted to hospital were found to have AKI [23]; this rate increases with 
sepsis (prevalence of >40%) [24] and in patients admitted to intensive 
care (prevalence >60%) [25]. It is more likely than not that individuals 
who are close to death and admitted to hospital for treatment will have 
some form of AKI.   
As expected, the only cause of death group that was not significantly 
different from the KRI group are individuals that are known to have 
suffered from diabetic ketoacidosis. In diabetic ketoacidosis individuals 
may exhibit dehydration and diabetic nephropathy, both of which are 
known to raise creatinine levels [26]. Simple post mortem testing can 
determine diabetic ketoacidosis so this can be identified if had not been 
previously diagnosed [27]. The diabetic ketoacidosis group illustrates the 
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medical issues that can cause AKI and also complicate the interpretation 
of renal impairment from post mortem sample analysis.  
As expected an increasing trend in kidney impairment with age was 
observed in the study data with both the creatinine and eGFR kidney 
impairment scoring. However the prevalence of individuals scored as 
having renal impairment was higher than that of individuals in the 
general population. When using eGFR (<60 mL/min/1.73 m2), the 
reference parameter that gave the highest sensitivity and specificity for 
scoring of renal impairment, there was on average a 13-18% higher 
prevalence of individuals in this scored as having “renal impairment” 
compared to the general population. This prevalence was even larger if 
eGFR (<90 mL/min/1.73 m2) was used (~30-32% higher). The lowest 
difference was with creatinine (6-7% higher). These results may show 
that the death process has a larger influence on the creatinine levels 
than previously expected and any interpretation of post mortem 
creatinine should be performed with extreme caution, especially the 
younger age groupings (<65 years) and also in females (see fig 3).    
 
The interpretation of a post mortem creatinine results may also be 
complicated by the sample analysed. Various post mortem samples 
have been reported in the literature as being suitable for the 
determination of creatinine levels including vitreous, pericardial fluid, 
cerebrospinal fluid, synovial fluid, post mortem serum and blood 
[7,8,21,28–30]. Studies have suggested the pericardial fluid creatinine 
concentrations correlate well with post mortem creatinine serum 
concentrations and that pericardial fluid should be used if post mortem 
serum is not available [21]. This study also notes that post mortem 
vitreous creatinine concentrations are significantly lower than those of 
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post mortem serum. It is possible that post mortem vitreous gives a 
creatinine concentration closer to that found at the time of death, as 
vitreous is sealed from the general circulation and this that may protect 
vitreous from changes in creatinine due to the death process. For 
example in animal studies creatinine blood concentrations have been 
shown to increase after death from ~18 mol/L at the time of death to 
~800 mol/L 2 hours after death [31]. This increase is most likely due to 
the release of creatinine from muscles into the blood in the early post 
mortem period [31,32]. Studies have also shown the shown that serum, 
blood and pericardial fluid creatinine concentrations are on average 
higher than the creatinine clinical reference ranges [7,8,21]. These 
postmortem increases in creatinine other body fluids may not be 
observed in vitreous as there is a time lag between any changes in the 
concentration of substances in blood and vitreous [33]. The possible 
postmortem elevation of creatinine in serum, blood and pericardial fluid 
in the post mortem period and any potential time lag between increases 
in vitreous creatinine would need to be confirmed in future studies. The 
use of serum, blood and pericardial fluid could also be problematic as 
based on the scored prevalence of renal impairment. In the general 
population these samples on average would give an increased likelihood 
of the scoring of the individual as being renally impaired as the median 
creatinine levels in pericardial fluid/serum values are ~ 4 to 5 fold larger 
than vitreous creatinine levels [21]. The use of pericardial fluid may also 
be problematic as this fluid is not routinely collected in all medico-legal 
centres.   
 
5. Conclusion 
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The biochemical analysis of post-mortem vitreous creatinine and 
subsequent calculation of eGFR is a useful adjunct to the standard 
testing that takes place during a post-mortem examination and can 
assist in death investigation. The data has shown that using eGFR (<60 
mL/min/1.73 m2) determined from vitreous creatinine, has the highest 
sensitivity and specificity for scoring renal impairment, but the use of a 
creatinine level of >120 mol/L gives a scoring of renal impairment 
closer to that found in the general population. It is, of course, always 
pertinent to interpret any results using a wealth of case information. 
Extreme caution should be exercised in cases where insufficient clinical 
information/history is available, particularly in cases in which there is 
suspected diabetic ketoacidosis, dehydration or hospitalisation prior to 
death.   
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Figure 1: Vitreous creatinine concentrations in relation to the cause 
of death and deaths in which there was known renal impairment. 
Mean, 25th and 75th percentiles, maximum and minimum. KRI – 
known renal impairment; RTC – road traffic collision. 
 
Figure 2: Calculated eGFR concentrations in relation to the cause 
of death and deaths in which there was known renal impairment. 
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Mean, 25th and 75th percentiles, maximum and minimum. KRI – 
known renal impairment; RTC – road traffic collision. 
 
Figure 3: Prevalence of scored kidney impairment in males and 
females by age group. The individuals were scored as having renal 
impairment based on either creatinine (> 120 µmol/L) or eGFR 
(<60mL/min/1.73m2).  
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Table 1: Common drugs that may accumulate during kidney 
impairment. More detailed and wider ranging information about the 
drugs that are excreted via the renal route can be found in the Renal 
Drug Handbook [3]. AKI – acute kidney injury, ACEi – angiotensin 
converting enzyme inhibitor, ARB – angiotensin receptor blocker, 
NSAIDS – non-steroidal anti-inflammatory drugs. 
Drug 
% excreted 
unchanged 
in urine 
Notes Reference 
ACEi/ARB - 
Known to reduce 
GFR further in 
AKI 
[3]  
Allopurinol  
Accumulation of 
active metabolite 
oxipurinol 
[3]  
Amisulpride 50   [3]  
Amphetamine 30   [34] 
Atenolol >90    [3]  
Benzodiazepines  
Risk of 
accumulation of 
activate 
metabolites 
 [3]  
Codeine - 
Accumulation of 
active metabolite 
morphine-6-
glucuronide 
 [3]  
Digoxin 50 – 75    [3]  
Dihydrocodeine 13 - 22 
Accumulation of 
active metabolite 
 [3]  
Dothiepin 56 
Accumulation of 
active 
metabolites 
possible 
 [3]  
Diuretics  
Risk of 
hyperkalemia 
and increase in 
mortality in AKI  
 [3,22]  
Gabapentin ~100    [3]  
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Heroin - 
Accumulation of 
active metabolite 
morphine-6-
glucuronide 
[34] 
Insulin  
Renal 
metabolism can 
decrease 
removal in AKI 
[3]  
Levetiracetam 66    [3]  
Lithium 95    [3]  
Methadone 15 – 60    [3]  
Metformin 100   [3]  
Methamphetamine 
43% (4-7% 
amphetamine) 
  [34] 
Mirtazapine 75    [3]  
Morphine - 
Accumulation of 
active metabolite 
morphine-6-
glucuronide 
 [3]  
NSAIDS  
Known to reduce 
renal function 
further in AKI 
 [3]  
Pregabalin 92-99    [3]  
Tramadol 90   [3]  
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Table 2: Summary of the result of statistical analysis of known renal impairment group with the various 
causes of death. Statistical analysis was 1 way ANOVA with Dunn’s multiple comparison post-hoc test 
(p<0.05).  KRI – known renal impairment; RTC- road traffic collision. 
Cause of Death 
Creatinine eGFR 
significantly 
different?  
P value 
summary 
significantly 
different?  
P value 
summary 
KRI vs. All Yes **** Yes **** 
KRI vs. Acute Traumatic Deaths Yes **** Yes **** 
KRI vs. Drowning Yes **** Yes **** 
KRI vs. Drug Toxicity Yes **** Yes **** 
KRI vs. Ethanol Toxicity Yes **** Yes **** 
KRI vs. Hanging Yes **** Yes **** 
KRI vs. Head Injury Yes **** Yes **** 
KRI vs. Ketoacidosis (alcoholic) Yes **** Yes ** 
KRI vs. Ketoacidosis (diabetic) No ns No ns 
KRI vs. RTC Yes **** Yes **** 
KRI vs. Stab Wounds Yes **** Yes **** 
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